

# Long-term insulin sensitivity and beta-cell function in short children born SGA treated with GH and GnRHa: Results of a randomized, dose-response trial

## CONCLUSIONS

- Combined GH/GnRHa treatment has no long-term negative effects on insulin sensitivity and  $\beta$ -cell function in young adults compared to only GH
- Started in early puberty, a GH dose of 2mg/m<sup>2</sup>/day results in a similar insulin sensitivity and  $\beta$ -cell function at AH as GH 1mg/m<sup>2</sup>/day

### Background

Children born SGA can benefit from combined treatment of GH and 2 years of GnRH analogue (GH/GnRHa). GnRHa treatment might have negative effects on insulin sensitivity. Long-term effects of combined GH/GnRHa treatment and GH-dose effects on insulin sensitivity and  $\beta$ -cell function at adult height (AH) are unknown.

### Aims

- To investigate insulin sensitivity and  $\beta$ -cell function during GH treatment, with or without 2 years of additional GnRHa.
- To assess whether a higher GH dose results in a similar insulin sensitivity and  $\beta$ -cell function at AH.

### Results

- At AH, insulin sensitivity and  $\beta$ -cell function were similar between children treated with combined GH/GnRHa and those treated with GH only
- A higher GH dose of 2mg/m<sup>2</sup>/day resulted in a similar insulin sensitivity and  $\beta$ -cell function as GH 1mg/m<sup>2</sup>/day


### I. Insulin sensitivity and $\beta$ -cell function at AH

|                                   | Total group     | GH/GnRHa        | GH              | P     |
|-----------------------------------|-----------------|-----------------|-----------------|-------|
| N                                 | 76              | 48              | 28              |       |
| Age                               | 17.4 (1.2)      | 17.4 (1.1)      | 17.4 (1.3)      | 0.853 |
| Si x 10 <sup>-4</sup> /min (mU/l) | 6.1 (5.2)       | 6.8 (5.8)       | 5.0 (3.9)       | 0.176 |
| AIR (mU/l)                        | 706.9 (564.4)   | 726.3 (616.7)   | 673.8 (470.2)   | 0.881 |
| DI (Si x AIR)                     | 2929.3 (1762.9) | 3159.4 (1871.4) | 2534.7 (1510.2) | 0.066 |
| Fasting glucose (mmol/l)          | 5.0 (0.5)       | 5.0 (0.5)       | 5.1 (0.6)       | 0.506 |
| Fasting insulin (mU/l)            | 13.6 (6.6)      | 13.6 (7.3)      | 13.7 (5.2)      | 0.752 |

### Methods

- 110 short SGA children, 11.4 years at start (59 girls)
- GH treatment until AH, mean follow-up 5.9 years
- At start of puberty
  - Height < 140cm → additional GnRHa for 2 yrs
    - GH/GnRHa-group: N=67 / GH-group: N=43
- Randomisation to GH 1mg/m<sup>2</sup>/day (~0.033mg/kg/d) or 2mg/m<sup>2</sup>/day (~0.067mg/kg/d)

### II. GH-dose effect on insulin sensitivity and $\beta$ -cell function in children with GH/GnRHa



### FSIGT

Frequently Sampled Intravenous Glucose Tolerance (FSIGT) test to measure insulin sensitivity (Si), acute insulin response (AIR) and beta-cell function (disposition index, DI)

This study was an investigator initiated study, supported by an independent research grant from Pfizer